Cantor Fitzgerald analyst Brandon Folkes last night initiated coverage of Veru with an Overweight rating and $6 price target. The company has built a pipeline of "compelling" assets, Folkes tells investors in a research note. He believes Veru's female condom business and Preboost have the potential to provide non-dilutive funding for the company to support continued investment in its pipeline. Further, at current share levels, little value is being ascribed to VERU-111, VERU-100, or Zuclomiphene citrate, which, if any are successful, could generate revenue in excess of $100M-plus each, Folkes contends. He believes "multiple near-term catalysts could transform" Veru.